

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30384 A1

- (51) International Patent Classification⁷: **A61K 39/00**, 39/02, C12N 15/62, 15/31, 15/63
- (21) International Application Number: **PCT/US00/29231**
- (22) International Filing Date: 23 October 2000 (23.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/161,193 22 October 1999 (22.10.1999) US
60/161,292 25 October 1999 (25.10.1999) US
- (71) Applicant (for all designated States except US): **ADVANCED MICROBIAL SOLUTIONS CORPORATION** [US/US]; 100 Inman Street, Cambridge, MA 02139 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MURPHY, John, R.** [US/US]; 130 Appleton Street, Boston, MA 02116 (US). **O'LEAR, Edward** [US/US]; 153 Spindle Hill Road, Wolcott, CT 06716 (US). **HARRISON, Robert, J.** [US/US]; 31 Green Street, Medfield, MA 02052 (US).
- (74) Agents: **FOLEY, Shawn, P.** et al.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP, 600 South Avenue West, Westfield, NJ 07090-1497 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **VACCINE COMPOSITIONS**

(57) Abstract: Disclosed are virulent or opportunistic prokaryotes in which metal ion-dependent gene regulation confers a growth or an infectious advantage. The prokaryote contains a DNA molecule containing a sequence encoding a dominant, metal ion-independent repressor protein or a partially metal ion independent repressor protein. The prokaryotes are formulated into vaccine compositions and administered to a human or other animal to enhance protective immunity against infectious and diseases caused by prokaryotes in which metal ion-dependant gene regulation confers a growth or an infectious advantage.

WO 01/30384 A1

531 Rec'd PCT/PTC 21 JUN 2001

VACCINE COMPOSITIONS

TECHNICAL FIELD

This invention relates to avirulent or attenuated microbes, their method of preparation, and their use in vaccines.

5 BACKGROUND ART

Infectious disease remains the largest cause of mortality in the world. A significant proportion of infectious disease associated morbidity and mortality results from bacterial pathogens. One widely applied technique used in controlling the spread and severity of bacterial infection is vaccination. Several notable vaccine
10 examples prevent a number of lethal microbial diseases, the DPT vaccine protects against diphtheria, pertusis and tetanus. The BCG or bacillus Calmette-Guerin vaccine is an example of an attenuated strain which is used worldwide to control the spread of tuberculosis (TB). A central issue in the development of safe and effective bacterial vaccines is the identification of protective antigens or attenuated strains of
15 bacteria which can promote the development of an immune response in the host yet in vaccine composition fail to cause morbidity or mortality in the host. A variety of methods can be employed to identify vaccine compositions including the production of attenuated or killed vaccine strains. Often these strains are in single genes which have been shown to play a role in virulence of the organism. Vaccine compositions
20 can include a live or fixed bacterial preparation of the mutant strain, the fixed protein, a fusion protein made of the virulence gene product and a suitable carrier and more recently the DNA encoding the protein.

Attenuated strains offer the potential of presenting a nearly intact complement of pathogen associated antigens to immune system. Furthermore these
25 antigens are likely to be presented in a bacterial context that mirrors that seen during early stages of infection by a virulent strain. This is evidenced by the ongoing practice of using live attenuated strains in the extensive vaccination of both human and livestock. For example BCG for tuberculosis and strain 19 against bovine brucellosis and Sterne's spore vaccine against anthrax in cattle.

30 The use of live vaccines can present developmental obstacles including the retention of unacceptable levels of virulence, the risk of reversion to

virulence during culture or *in vivo* and lack of efficacy. The ability to create more effective live or attenuated vaccines is in part dependent upon the ability to control and restrict the expression of virulence determinants so as to create vaccine strains that are protective and safe.

5 Bacteria respond to nutritional stress by the coordinated expression of different genes. This facilitates their survival in different environments. Among these differentially regulated genes are the genes responsible for the expression of virulence determinants. The selective expression of these genes in a sensitive or susceptible host allows for the establishment and maintenance of infection or disease.

10 Virulence include genes which encode toxins, colonization factors and genes required for siderophores production or other factors that promote this process.

 The expression of virulence genes in bacteria therefore enable the organism to invade, colonize and initiate an infection in humans and/or animals, however, these genes are not necessarily expressed constantly (constitutively). That
15 is, the bacterium is not always orchestrating gene expression patterns to maximize "infectious" potential. In many circumstances, the expression of virulence genes is controlled by regulatory circuitry which include repressor proteins and a corresponding operon or operator. One class of repressors which is activated upon binding to or forming a complex with a transition metal ion such as iron, zinc or
20 manganese is thought to control the expression of a subset of genes in a number of Gram positive organisms. When such repressors are activated and associated with virulence gene expression in pathogens, they bind the operator sites thereby preventing production of virulence determinants.

 Virulence determinants are most often expressed when the bacterial
25 pathogen is exposed to environmental stress such nutritional restriction. An iron-poor environment is an example of such a condition. In many eucaryotes such an environment is the norm, insufficient iron is present to maintain the repressor in its active state. In the inactive form, the repressor cannot bind to target operators. As a result, virulence genes are de-repressed and the bacterium is able to initiate, establish,
30 promote or maintain infection.

The expression of these virulence determinants is in many bacterial species co-regulated by metal ions. In most instances the metal co-factor that is involved *in vivo* is iron [but can include zinc, nickel, manganese, cobalts]. In the presence of iron, the repressor is activated and virulence gene expression is halted.

5 This pattern of gene regulation is illustrated by the following example. The bacterium that causes diphtheria produces one of the most potent toxins known to man. The toxin is only produced under conditions of iron deprivation. In the presence of iron, the bacterial repressor (which in this species is known as diphtheria toxin repressor protein, abbreviated "*DtxR*") binds iron and undergoes
10 conformational changes that activate it and allow it to dimerize and bind a specific DNA sequence called the tox operator. The tox operator is a specific DNA sequence found upstream of the gene that produces the diphtheria toxin, thereby preventing its expression. Typically, during infection of a human host the diphtheria bacillus (or other pathogenic/opportunistic bacteria) grows in an environment that rapidly
15 becomes restricted in several key nutrients. Paramount among these essential nutrients is iron, and when iron becomes limiting the diphtheria bacillus begins to produce the toxin. Moreover, the constellation of virulence genes that *DtxR* controls becomes de-repressed and the diphtheria bacillus becomes better adapted to cause an infection. In the case of diphtheria, the toxin kills host cells thereby releasing
20 required nutrients including iron.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 aligns the amino acid sequences of *DtxR*, *IdeR* and *SirR*.

Figure 2 aligns amino acid sequences of various *IdeR*/*SirR* Homologues found in various species of mycobacterium.

25 Figure 3 aligns and compares the amino acid sequence of various homologues of various *DtxR* type repressors, including *DtxR* from *Brevibacterium lactofermentum* (Bl), *DtxR* from *Corynebacterium diphtheriae* (Cd), *IdeR* from *Mycobacterium tuberculosis* (Mt), *M. leprae* [P], *M. smegmatis* [P]; *DesR* from *Streptomyces lividans* (Sl), *M. tuberculosis* *SirR*, *Staphylococcus aureus* (Sa) *SirR*, *S.*
30 *epidermidis* *SirR*, *Enterococcus faecalis* *DtxR* homologue [P]. The *DtxR* homologues from the *Streptococcus gordonii*, *S. mutans*, *S. pneumoniae* and *S. pyogenes*. The

consensus amino acid sequences between these members of the DtxR family of iron-dependent repressors is indicated. *, metal ion coordination residues in the Primary site; #, metal ion coordination residues in the Ancillary site; @, the single amino acid residue that interacts with a base in the binding of DtxR dimers to the *tox* operator.

- 5 AMS has clones of *M. tuberculosis* IdeR, *S. aureus* and *S. epidermidis* SirR, and DtxR homologues from *Enterococcus faecalis*, *S. mutans*, *S. pneumoniae*, and *K. pneumoniae*.

Figure 4: Western blot of cell lysates incubated with polyclonal antibody against DtxR. Lane 1 shows purified DtxR (25.3 kDa). Lanes 3 and 5: lysates from wild type *M. smegmatis* and *M. tuberculosis*, respectively, expressing native IdeR (25.2 kDa.). Lane 4: lysate from the *M. smegmatis* heterodiploid harboring pNBV1/SAD expressing both DtxR(E175K) and IdeR. The molecular weight masses, determined by size standards, are shown at left.

Figure 5: Virulence comparison of wild type *M. tuberculosis* and *M. tuberculosis* DtxR(E175K) mutant. Panel A shows the log CFU of the homogenized spleens of mice sacrificed at 4 week intervals. Panel B shows the log CFU of homogenized lungs at 4 week intervals. Each point represents the mean log CFU of 5-6 mice \pm 1 standard deviation (error bars). Asterisks denote statistically significant differences between groups at a given time point.

Figure 6: Panel A: a 10 week-old representative colony of wild type *M. tuberculosis* (strain CDC1551) on 7H10 agar. Panel B: a 10 week-old representative colony of *M. tuberculosis* DtxR(E175K) on 7H10 agar.

Figure 7: Alignment of the "iron box" consensus sequence, known DtxR binding sites, and putative *M. tuberculosis* DtxR/IdeR binding sites identified by an *in silico* genome search. The "consensus sequence" at the top of the figure represents the compilation of the 9 aligned sequences in the figure. The "published consensus" is drawn from the literature. Gene homologues of the downstream ORFs are shown on the right.

Figure 8: Autoradiographs of gel binding assay between DtxR and putative *M. tuberculosis* DtxR/IdeR binding sites. 100 bp ³²P-end-labeled DNA fragments containing *toxO* (lanes 1 & 2), IB-1 (lanes 3 & 4), IB-2 (lanes 5 & 6), IB-

3 (lanes 7 & 8), IB-4 (lanes 9 & 10), IB-5 (lanes 11 & 12) separated in a non-denaturing 6% polyacrylamide gel. Odd numbered lanes contain DNA only ("unbound"), and even numbered lanes contain DNA pre-incubated with purified DtxR ("bound").

5 Figure 9. Virulence of *S. aureus* is altered in a mouse skin lesion model following 8 days of *in vivo* incubation. 8.0 log CFU of the parent strain MA2181 [RN6390 carrying empty shuttle vector pSPT181] and 7.8 log CFU of the complemented MA2004 strain carrying DtxR E175K were injected sub-cutaneously on day 1 abscess size[mm] was measured each day over 8 days and on the last day
10 the abscess was removed and the number of CFU were determined. CFU [a.] and abscess size [b.] were compared between groups.

SUMMARY OF THE INVENTION

A first aspect of the present invention is directed to a composition containing a virulent or opportunistic prokaryote in which metal ion-dependent gene
15 regulation confers a growth or an infectious advantage. The prokaryote contains a recombinant DNA molecule comprising a promoter in operable association with a sequence encoding a dominant, metal ion-independent repressor protein or a partially metal ion independent repressor protein, and a carrier. In preferred embodiments, a promoter is constitutive in nature. In other preferred embodiments, the DNA
20 molecule contains a sequence encoding a metal ion-independent DtxR protein or a partially metal ion-independent DtxR protein. In yet other preferred embodiments, the bacterium is a member of the genus *Mycobacterium*, *Staphylococcus* or *Streptococcus*.

The second aspect of the present invention is directed to a method of
25 enhancing protective immunity against infection or disease caused by an opportunistic or virulent prokaryote pathogen in which metal or metal ion-dependent gene regulation confers a growth or an infectious advantage. The method entails administering compositions to the animal. In preferred embodiments, the animal is a human. In other preferred embodiments, the compositions are administered
30 prophylactically *e.g.* prior to the onset of the infection or disease. In yet other

preferred embodiments, the prokaryote contained in the compositions is in a live or killed form.

A relatively aspect directed to is a method of attenuating or reducing the severity of an infection or a disease caused by an opportunistic or virulent prokaryotic pathogen in which metal or metal ion-dependent gene regulation confers a drug or an infectious advantage. The method also entails administering the compositions to the animal, preferably prior to the onset of the infection or disease condition.

Yet another aspect of the present invention is directed to isolated and purified DNA molecules consisting essentially of a sequence encoding a metal or metal ion-independent or a partially metal or metal ion-independent DtxR or homologue thereof. Preferred homologues are IdeR and SirR. In other preferred embodiments, the molecule is placed in an expression cassette or a vector (e.g., a plasmid) so as to be in operable association with a promoter element, especially a constitutive promoter. Vectors containing the DNA molecules and prokaryotes transformed with DNA molecules (including cultures thereof) are also provided.

A further aspect of the present invention is directed to a method for preparing the compositions. The method entails obtaining a DNA molecule encoding a metal ion-independent repressor protein or a partially metal ion-independent repressor protein. The wild type protein, in its native state, is a metal ion-dependent gene regulator and confers upon a virulent or opportunistic prokaryote a growth or an infectious advantage. The DNA molecule is linked to a promoter, preferably a constitutive promoter, and then introduced into such a virulent or opportunist prokaryote. The DNA is expressed in the prokaryote and inhibits metal ion-dependent gene regulation.

The present invention entails the incorporation of an exogenous DNA encoding a dominant, metal ion (hereinafter "metal") independent or partially metal ion independent mutant repressor into an otherwise virulent or opportunistic prokaryote in which metal ion-dependent gene regulation confers a growth or an infectious advantage. Such prokaryotes include gram-positive and gram-negative bacteria. Without intending to be bound by theory, Applicants believe that the

dominance of the metal-independent mutant repressor subverts the normal patterns of gene regulation (under the control of the native, metal-dependent repressor), thereby creating a recombinant prokaryote that is attenuated or avirulent relative to the wild-type prokaryote. That is, the exogenous mutant repressor renders inoperable or significantly inoperable the normal metal dependent genetic circuitry that occurs *in vivo* and causes in whole or in part the prokaryote carrying such a recombinant genetic complement to become less infectious or non-pathogenic. This property renders the recombinant prokaryote suitable for use as an immunogen to be formulated into a vaccine.

10 BEST MODE OF CARRYING OUT THE INVENTION

To prepare the compositions of the present invention, a determination is made as to whether or not the species of interest regulates virulence determinant expression as a function of available metal ion concentrations. This can be done, for example, by screening protein from the bacteria of interest with an antibody for DtxR or other DtxR like proteins to ascertain if a homologous repressor exists in the species. This can also be accomplished using specialized techniques like gel mobility shift assays or the method disclosed in Sun et al, PNAS 95:14985-14990 (1998), or more common gene expression monitoring methods such as northern analysis, and PCR. If the species of interest employs a DtxR type repressor then the expression of this repressor can be elucidated by one of the aforementioned methods and the techniques described here can be employed to build a recombinant attenuated strain for vaccine purposes.

Preferred prokaryotes are Gram positive bacterial species, and particularly those listed below. These species contain DtxR like metal dependent repressors. Specific examples include:

S. pneumoniae	S. agalactia	S. equisimilis
S. meningitis	S. bovis	S. anginosus
S. pyogenes	S. salivarius	S. sanguis
S. suis	S. mutans	Enterococcus faecalis
Staphylococcus species		
S. aureus	S. epidermitis	

Mycobacteria species

M. tuberculosis	M. avium complex	M. kansasii
M. leprae	M. scrofulaceum	M. fortuitum
M. ulcerans	M. marinum	M. bovis
M. microtii	M. africanum	M. paratuberculosis

Actinomyces species

A. pyogenes	A. israelii	A. bovis
A. viscosus	A. hordeovulneris	A. gerencseriae
A. naeslundii	A. odontolyticus	and others

Listeria monocytogenes**Propionibacterium acnes****Erysipelothrix rhusiopathiae**

The repressor which typifies the class of genetic regulators in the above listed bacteria is the diphtheria toxin repressor DtxR in *C. diphtheriae*, the causative agent of diphtheria. DtxR is a metal dependent repressor which under limiting concentrations of metal ions becomes inactivated permitting the derepression of a number of virulence genes including diphtheria toxin. This pattern of gene expression is common to both Gram positive and Gram negative bacteria. In Gram positive bacteria, DtxR or DtxR homologues appear to be important metal dependent regulators whereas in Gram negative bacteria, Fur is the significant metal dependent regulator. Some species of pathogen appear to contain both DtxR and Fur like metal dependent repressors. In each case, the presence of repressor bound metal ion is critical for appropriate activity of the repressor which coordinates the repression of gene expression *in vivo*.

The prokaryotes of the present invention having a dominant, metal ion independent or partially metal ion independent mutant of the repressor (such as the diphtheria toxin repressor gene *DtxR* or a *DtxR*-homolog e.g., IdeR, SirR) will render the pathogen unable to effectively establish a full infection. (Hill et al, (1998) Infection and Immunity 66: 4123-4129; and Dussurget et al (1996) Molecular Microbiology 22 536-544; and Pohl et al (1999) J. Molecular Biology 285 1145-1156). Apart from the targeting vector sequences or plasmid DNA used to generate

the attenuated strains and the mutant repressor gene, the recombinant prokaryote is in all other aspects identical genetically to the wild-type organism. The presence of the dominant iron independent repressor results in a phenotypic change in the organisms virulence.

5 In preferred embodiments, the exogenous DNA comprises a sequence encoding a dominant, metal-independent DtxR or a functional fragment, variant or homologue thereof (collectively referred to as "a DtxR protein"). DtxR is a metal iron-dependent DNA-binding protein having a deduced molecular weight of 25,316 and which functions as a global regulatory element for a variety of genes on the *C.*
10 *diphtheriae* chromosome. See Tao *et al.*, Proc. Natl. Acad. Sci. USA 89:5897-5901 (1992); Schmitt *et al.*, Infect. Immun. 59:1899-1904 (1994). For example, *DtxR* regulates the expression of the diphtheria toxin structural gene (*tox*) in a family of closely related *Corynebacteriophages*. The repressor has also been shown to regulate a number of other iron dependent genes. The gene for DtxR and a number of DtxR
15 homologues have been cloned and sequenced. A number of detailed structural and functional studies have been performed to analyse DtxR. See Boyd *et al.*, Proc. Natl. Acad. Sci. USA 87:5968-5972 (1990); Schmitt *et al.*, *supra*. *DtxR* is activated by divalent transition metal ions (*e.g.*, iron). Once activated, it specifically binds the diphtheria *tox* operator and other related palindromic DNA targets. See Ding *et al.*,
20 Nature Struct. Biol. 3(4):382-387 (1996); Schiering *et al.* Proc. Natl. Acad. Sci. USA 92:9843-9850 (1995); White *et al.*, Nature 394:502-506 (1998). DNA sequences encoding DtxR from various *C. diphtheria* strains are defined by accession numbers M80336, M80337, M80338, and M34239.

Functional fragments or variants of *DtxR*, when activated, retain their
25 binding activity to the *tox* operator (or a functional fragment thereof) and/or the *DtxR* consensus binding sequence. *DtxR* fragments and variants can be identified by standard techniques such as mutagenesis. Tao *et al.*, Proc. Natl. Acad. Sci. USA 90:8524-8528 (1993) identified important residues for DtxR function and analysis. Other variants are disclosed in Tao *et al.*, Mol. Microb. 14(2):191-197 (1994). Tao
30 discloses that some *DtxR* alleles have different amino acid sequences, *e.g.*, the *DtxR* allele from strain 1030(-) of *C. diphtheriae* was found to carry six amino acid

substitutions in the C-terminal region, none of which affected the iron-dependent regulatory activity of *DtxR* (1030) (Tao II). See also Boyd *et al.*, J. Bacteriol. 174:1268-1272 (1992) and Schmitt *et al.*, Infect. Immun. 59:3903-3908 (1991). Thus, *DtxR* fragments and variants may be mutagenized to an iron-independent genotype.

Many other bacterial species employ regulatory circuits and repressor proteins that exhibit high degrees of sequence similarity to *DtxR*. (Posey *et al* (1999) Proc Natl Acad Sci 96 10887-10892, Que and Helmann (2000) Molecular Microbiology 35 1454-1468, Kitten *et al*, (2000) Infect and Immun 68 4441-4451, Manabe (1999) Proc Natl Acad Sci 96 12844-12848. Thus, dominant, metal-independent *DtxR* homologues may also be employed in the methods of the present invention. Iron dependent regulator (*IdeR*), isolated from *Mycobacterium tuberculosis*, has been found to share 60% amino acid homology with *DtxR*. See Schmitt *et al.*, Infect Immun. 63(11):4284-4289 (1995). See also Doukhan *et al.*, Gene 165(1):67-70 (1995), which reports and references *DtxR* homologs in *Mycobacterium smegmatis* and *Mycobacterium leprae*. *DtxR* homologues have been cloned in other gram-positive organisms including *Brevibacterium lactofermentum* and *Streptomyces lividans*. See Oguiza *et al.*, J. Bacteriol. 177(2):465-467 (1995); Günter *et al.*, J. Bacteriol. 175:3295-3302 (1993); and Schmitt *et al.*, Infect. Immun. 63:4284-4289 (1995). Staphylococcal iron regulated repressor (SirR), native to *Staphylococcus epidermitis*, is another known *DtxR* homologue. These proteins bear a common feature they share a remarkably high sequence similarity in the respective N-terminal 139 amino acid regions, especially those amino acids involved in DNA recognition and transition metal ion coordination.

A collection of accession numbers for sequences that are either homologous to *DtxR* or contain a consensus tox O/P is presented in Table 1. See <http://www.ncbi.nlm.nih.gov/BLAST> and <http://www.ncbi.nlm.nih.gov/unfinishedgenomes.html>. See also, Altschul, *et al.*, J. Mol. Biol. 215:403-410 (1990); Gish, *et al.*, Nature Genet. 3:266-272 (1993); Madden, *et al.*, Meth. Enzymol. 266:131-141 (1996); Altschul, *et al.*, Nucleic Acids Res. 25:3389-3402 (1997); and Zhang, *et al.*, Genome Res. 7:649-656 (1997). This

high degree of sequence similarity and homology is indicative of a widely conserved metal ion dependent regulatory pathway employing *DtxR*-family repressors. It is noteworthy that many important human and animal pathogens are present in this collection of bacteria. Dominant metal independent repressors can be generated and
5 introduced into a prokaryote. Such mutants alter virulent phenotype *in vivo* and may be used as vaccines.

Table 1

DtxR Homologs and Species with DtxR Binding Sites

	Pathogenic Human/Veterinary Applications	Other
5	CAA67572 S. epidermitis	L35906 C. glutamicum
	Gi 1777937 T. pallidum	Z50048 S. pilosus
	CAA15583 M. tuberculosis	Z50049 S. lividans
	U14191 M. tuberculosis	
	L78826 M. leprae	
10	M80336 C. diphtheriae	
	M80337 C. diphtheriae	
	M34239 C. diphtheriae	
	M80338 C. diphtheriae	
	AAD18491 C. pneumoniae	
15	Gi 3328463 C. trachomatis	
	TIGR 1280 S. aureus	
	OUACGT S. pyogenes	
	Sanger 518 B. bronchoseptica	
	Sanger 1765 M. bovis	
20	Sanger 520 B. pertussis	
	WUGSC K. pneumoniae	
	TIGR 1351 E. faecalis	
	AE000783 B. burgdorferi	
	TIGR1313 S. pneumoniae	
25	Snager 632 Y. pestis	
	AE001439 H. pylori	
	TIGR 1752 V. cholera	
	TIGR1097 C. tepidum	
30	U14190 M. smegmatis	
	Gi 2621260 M. thermoautotrophicum	
	Gi 2622034 M. thermoautotrophicum	
	M50379 M. jannaschi	
	Q57988 M. jannaschi	
35	O33812 S. xylosus	
	Gi 264870 A. fulgidus	
	Gi 2648555 A. fulgidu	
	Gi 2650396 A. fulgidus	
	Gi2650706 A. fulgidus	
40	BAA79503 A. permix	
	CAB49983.1 P. abyssi	
	BAA30263 P. horikoshi	
	AL109974 S. coelicolor	
45	L35906 B. lactofermentumStanford 382 S. meliloti	
	TIGR 76 C. crescentus	
	TIGR 24 S. putrificacicus	
50	AE000657 A. aeolius	
	TIGR 920 T. ferr oxidans	

Preferred gram positive pathogenic bacteria include *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium paratuberculosis*, *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Staphylococcus aureus*, *Staphylococcus epidermitis*, *Streptococcus mutans* and *Streptococcus pneumoniae*. The preferred
5 dominant DtxR (or homologue) repressors are metal independent and contain a single amino acid change to convert the native, metal-dependent repressor to metal independent regulation.

A preferred metal independent repressor is the mutant E175K DtxR. This same substitution can be made in DtxR fragments and variants. In addition,
10 DtxR homologues that exist in other bacterial species may be mutated at the corresponding position. Figure 1 displays the degree of amino acid homology between DtxR and to homologous proteins, IdeR from *Mycobacterium tuberculosis* and SirR from *Staphylococcus epidermitis*. As shown in fig. 1, the single amino acid at residue E175K in DtxR, the glutamic acid is conserved in IdeR hence a 177K
15 mutation of IdeR would most likely have the analogous functional implications. Dussurget et al (1996) Molecular Microbiology 22 536-544 and Pohl et al(1999) J. Molecular Biology 285 1145-1156).

Figure 2 presents a comparison of IdeR/SirR homologues found in other mycobacterium that cause significant disease including; *M. tuberculosis*, *M smegmatis*, *M. leprae* and a SirR clones from *M. tuberculosis*. Shown in bold is the
20 conserved glutamic acid in the C-terminal region of these repressors that can potentially be mutated to yield an iron independent version of each of these repressors. Thus, corresponding mutations would be expected to result in a metal-independent genotype. Figure 3 illustrates the amino acid sequence homology of a
25 number of homologous DtxR type repressors. These repressors differ slightly in their sequence length and the ClustalW program used to carry out a logical alignment adjusts for these differences. See NCBI [www.ncbi.nlm.nih.gov] web site and Baylor College of Medicine Search Launcher[http://.gc.bcm.tmc.edu] for details. Indicated by Bold 'E' is the highly conserved glutamic acid residue in the C-terminus
30 of these repressors which is a possible target for generating metal ion independent versions of each of these repressors.

A combination of standard techniques may be used to make other dominant, metal-independent DtxR proteins, namely mutagenesis followed by tests to determine if a given mutant binds the corresponding operator. A number of theoretical mutations can be incorporated which will convert the repressor to be metal-independent. To generate repressor DNA clones with a random distribution of mutated bases, any of several saturation mutagenesis techniques can be utilized. DNA, plasmid preparation, and DNA sequence analysis are performed according to standard methods. The saturation of random mutations throughout the length of repressors DNA of interest introduces random changes in amino acid sequence throughout the encoded protein that potentially can confer a metal independent phenotype on the mutant repressor.

Several approaches can be pursued to generate effective vaccines relying upon DtxR. In preferred embodiments, DtxR homologues are identified in a species of interest. This can be achieved by performing PCR on genomic DNA from the species of interest using primer sets compatible to conserved domains within the DtxR family. Specific sequences may be composed of degenerate primers flanking the iron binding domain, or the helix-turn-helix domain. Cloning may also be performed from phage libraries using DtxR conserved regions as probes, utilizing the PSTD system or by *in silico* searches and de novo *in vitro* synthesis.

The DtxR has a domain structure which is composed of a helix-turn-helix domain, and N-terminal iron binding domain. There are a number of additional highly conserved sequences including a proline rich region which lies between the HLH and C-terminal domain. The polymerase chain reaction allows the amplification of any DNA target from a population of DNA molecules if compatible oligonucleotide primers can be identified. While a number of software programs are available to assist in the design of effective primers, optimal primer sets often require empirical determination.

Cloning of DtxR homologues from any given species can be achieved by mixing primers with genomic DNA isolated from the species of interest in the appropriate ratios in the presence of free oligonucleotides, optimized buffer conditions and the TAQ polymerase (or a suitable version of a thermostable

polymerase) and cycling the reaction conditions with the aid of an automated thermocycler. The PCR reaction generates a series of products that represent target DNA sequences that are bounded by sequences homologous to the selected 5' and 3' primers. Thus, the selection of primers which lie within conserved regions of DtxR
5 will likely bind under the appropriate conditions to homologous DNA that will likely represent a gene or domain similar to that of DtxR.

DtxR homologues may further be identified by screening genetic libraries of a given species created in *E. coli*. Pathogen libraries can then be screened by radio-labeled probes generated from DtxR clones, oligonucleotides from the DtxR
10 sequence, or protein assays using antibodies directed against DtxR.

Sun, *et al.* have developed a screen can be used as a positive selection assay for DtxR homologues. See Sun, *et al.*, PNAS 95:14985-14590 (1998). This screen requires only the generation of a gDNA library from the species of interest be transformed into the appropriate background host. Colonies which appear upon
15 selection by chloramphenicol can only arise if a functional DtxR like protein is being expressed from the cloned gDNA fragment. Once a clone has been identified, sequencing and sequence analysis will reveal a gene which has at least partial sequence homology to DtxR and functional equivalence based on the PSDT screen developed by Sun *et al.*

20 Once identified, these clones become the substrates from which a vaccine strain is assembled. Two approaches are preferred. The first approach is a knock-in approach which is coupled with *in vitro* mutagenesis or PCR mutagenesis. The knock-in approach is focused on generating strains having dominant activated repressors. These strains contain a defective or altered copy of DtxR or a DtxR
25 homologue that containing at least one but up to several mutations resulting in a repressor that recognizes and binds the toxAPO or suitable cognate binding sites in both the presence and absence of iron (or the appropriate metal ion). These metal ion independent mutants are cloned into suitable vectors (e.g., targeting vectors having a selectable marker and restriction sites) to develop strains expressing dominant
30 activated DtxR constitutively. These plasmids are used to generate knock-in vaccine strains, essentially altered forms of the wild-type virulent strain differing in only the

presence of a dominant activated DtxR or DtxR-homologous repressor. The constructs can also be used in gene replacement strategies in which the mutant metal independent repressor gene replaces the endogenous wild type gene. (Howard et al (1995) Gene 166 181-182, Jacobs et al (1991) Mthds in Enz 204 537-555., Rubin et al (1999) Proc Natl Acad Sci 1644-1650), Caparon and Scott (1991) Mthds in Enz 204 556-586, Norgren, Caparon and Scott, (1989) Infect and Immun 57 3846-3850, Biswas et al, (1993) J Bact. 175 3625-3635. Such a strain is effectively avirulent since its ability to up-regulate iron dependent virulence genes has been crippled.

Metal ion independent clones can be sequenced to identify the specific amino acid changes that confer the iron independent phenotype. Again, a preferred mutant is characterized by a change from glutamic acid to lysine at position 175 in native DtxR. In general, however, multiple mutations are also embraced by the present invention. Multiple mutations are advantageous because they greatly decrease the likelihood of reversion to wild-type function. This likelihood becomes statistically more akin to that of a strain which has all of its iron regulated genes knocked out. Multiple mutations either clustered or distributed through out the repressor can result in the same phenotype. For example, a double mutant DtxR with the replacement of asparagine at position 130 with glycine and the glutamine at position 181 with arginine was also identified with a metal independent phenotype. In addition a mutant with an intermediate phenotype was also identified having a total of six mutations[valine 5 to isoleucine, aspartic acid 110 to glutamic acid, valine 112 to phenylalanine, isoleucine 153 to threonine, aspartic acid 197 to glutamic acid, threonine 220 to alanine]. These mutations produced a partially metal dependent phenotype. Thus, the present invention also embraces the use of partially metal ion-independent repressors. It is believed that expression of these repressors allow the partial colonization of the host which promotes the development of a robust protective immune response. The metal dependent phenotype can be readily revealed by linking a readily assayed reporter gene to the *tox O/P* in *E. coli* and a assessing reporter function under metal and metal conditions as described by Sun, *et al*.

More generally, however, the DtxR mutants of the present invention are not limited to those characterized by single or multiple amino acid substitutions.

Insertion and deletion mutants are also contemplated. These mutants may be identified using the instantly disclosed techniques as well.

Strains and putative mutants can be tested for metal independent phenotype by several approaches including the PSTD screen described in Sun *et al.*

5 Additional methods of determining if conversion to iron independent phenotype include computer modeling, structural analysis, dimerization analysis by gel electrophoresis, DNA binding by electrophoretic mobility shift assay, transcriptional profiling, tissue culture and in vivo virulence assays. Ultimately, *in vivo* screening will be required to determine if the iron independent phenotype is stable in a host
10 environment and to determine if virulence is attenuated. Attenuated virulence can be defined by biochemical, physiological and immunological markers but will minimally include an assessment of ED₅₀ or LD₅₀ in wild-type, knock-in, replacement and recombinant strains.

A second rational mutagenesis strategy can be utilized to generate
15 metal-independent mutants. This strategy relies upon the conserved domain structure of the DtxR family of repressors. Several DtxR iron independent mutants have been identified and published. These mutants define two classes of iron independent mutations which are likely to alter iron dependent regulation in DtxR homologues. Site directed mutagenesis of the analogous amino acid residues in DtxR homologues
20 may have the same iron independent phenotype. In addition as the data from structural studies grows it will likely be possible to construct mutants that replace amino acids involved in the coordination of iron binding or dimerization that result in an iron independent phenotype.

Mutagenesis is then carried out to generate a library of the desired
25 mutants of this DtxR homologue of interest. Identification of iron independent mutants from this population is achieved by using the PSTD system. Using the cloned and mutant homologue genes, one can select for the growth of colonies in the PSTD strains in the presence of dipyridyl (DP). Dipyridyl chelates iron from the media and therefore leads to the disassociation of DtxR homologues from the
30 regulatory regions of the genetic elements in the PSTD screen. As a result, all iron

dependent repressors will not be able to survive chloramphenicol selection, in contrast iron independent mutants will grow.

Mutants of DtxR are generated in accordance with standard techniques. Polymerase chain reaction (PCR) mutagenesis of the *dtxR* gene is described in Vartanian *et al.* [Vartanian, J.-P., Henry, S., & Wain-Hobson, S. (1996) Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. *Nucleic Acid Res.*, 24, 2627-2631.]. Briefly, *Bgl*II-tagged primers 1515 (5'-ACCAGATCTGCCGAAAACTTCGA-3') and 1516 (5'-ACCAGATCTCCGCCTTTAGTATTTA-3') were used to PCR amplify *dtxR* from plasmid pRDA which carries the wild type *dtxR* operon. The products of the amplification were then digested with *Bgl*II and ligated either into *Bgl*II-linearized pSC6M1 and transformed into *E. coli* TOP10/ λ RS65T, or ligated into *Bam*HI digested pBR322 and transformed into *E. coli* TOP10/ λ RS65T/pSC6. Iron-independent mutants of DtxR were then selected on LB agar plates supplemented with Cm and DP in accordance with the procedure described in Sun, *et al.*

Broadly speaking, these mutations should conserve the structural integrity and maintain the ability of the repressor to bind and repress gene expression through the consensus or near consensus *tox* P/O sites. Bacterial clones containing mutagenized *dtxR* can be analysed by DNA sequencing and used in functional biochemical assays such as electrophoretic mobility shift assay, native gel analysis and glutaraldehyde crosslinking studies to reveal the activated state of the repressor in question under metal limiting conditions. This can be determined through gel shift analysis or by functional assays, but it is preferably made using the one-step method described by Frigg, *et al* [Sun, L., vanderSpek, J. & Murphy, J. R. (1998)*Proc. Natl. Acad. Sci. USA*, 95, 14985-14990]. For gel shift analysis the native *tox* operator (i.e., 5'-ATAATTAGGATAGCTTTACCTAATTAT-3') is a 27 base pair interrupted palindromic sequence upstream of the diphtheria *tox* structural gene can be used as a probe. This sequence features a 9-base pair inverted repeat sequence that is separated by 9 base pairs. See Kaczorek *et al.*, *Science* 221:855-858 (1983); Greenfield *et al.*, *Proc. Natl. Acad. Sci. USA* 80:6853-6857 (1983); Ratti *et al.*, *Nucleic Acids Res.* 11:6589-6595 (1983); and Fourel *et al.*, *Infect. Immunol.*

57:3221-3225 (1989). It overlaps both the -10 region of the *tox* promoter and the transcriptional start sites at -45, -40 and -39 upstream of the diphtheria toxin structural gene. See Boyd *et al.*, J. Bacteriol. 170:5940-5952 (1988). The minimal essential DNA target site, i.e., 5'-GTAGGTTAGGCTAACCTAT-3', is a 19 base pair sequence that forms a perfect palindrome around a central C or G -- is described in 5 Tao and Murphy, Proc. Natl. Acad. Sci. USA 91:9646-9650 (1994). Additional probes are variants of ToxO based on the *DtxR* consensus-binding sequence (5'-ANANTTAGGNTAGNCTANNCTNNNN-3'). Variants are defined by the following sequence: 5'-TWAGGTTAGSCTAACCTWA-3'. Thus the function of the repressor and mutant can be defined by recognition and binding or regulation of gene 10 expression via the sequences or variants described above.

Once a dominant, metal-independent DtxR DNA clone is identified, it can be produced and manipulated in accordance with techniques known in the art. For example, they may be generated using standard chemical synthesis techniques. 15 See, *e.g.*, Merrifield, Science 233:341-347 (1986) and Atherton *et al.*, Solid Phase Synthesis, A Practical Approach, IRL Press, Oxford (1989). Preferably, they are obtained by recombinant techniques. Standard recombinant procedures are described in Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Second ed., Cold Spring Harbor, New York, and Ausubel *et al.*, (eds.) Current Protocols in 20 Molecular Biology, Green/Wiley, New York (1987 and periodic supplements). The appropriate sequences can be obtained from either genomic or cDNA libraries using standard techniques. DNA constructs encoding the DNA gene segments may also be prepared synthetically by established methods, *e.g.*, in an automatic DNA synthesizer, and then purified, annealed, ligated and cloned into suitable vectors. 25 Atherton *et al.*, *supra*. Polymerase chain reaction (PCR) techniques can also be used. See *e.g.*, PCR Protocols: A Guide to Methods and Applications, 1990, Innis *et al.* (ed.), Academic Press, New York.

The DNA encoding the mutant metal-independent repressor is operably linked to a promoter element. Preferred promoters include the endogenous 30 DtxR promoter or the promoter of the DtxR homologue in question or any suitable constitutive promoter functional in the species of interest. the constructs may further

contain an associated selectable marker gene to follow maintenance of the mutant construct. For example in Mycobacterial species a hygromycin resistance gene in an *E. coli* shuttle vector provides great utility for cloning and expression of a mutant IdeR or another dominant metal ion independent repressor [DtxR E175K]. [Bishai *et al* Gene 1995 166:181-182] In other embodiments, the vectors also contain a copy of a gene lethal to the bacterium under the control of the metal dependent regulator. Examples of such genes include antibiotic genes, restriction enzymes, proteolytic enzymes, lethal phage genes or any gene whose product once expressed would kill the bacterium. The presence of this "suicide cassette" further ensures that vaccines containing the prokaryote in live form do not revert to any significant degree and cause disease *in vivo*.

Suitable cloning and expression vectors are readily available from a number of sources. In preferred embodiments, the construct is introduced into the prokaryote by way of a vector, in which case the construct may be formed prior to or upon introduction of the DNA into the vector. A vector for a given species must contain an origin of replication, a selectable marker and a functional promoter by which the mutant metal ion independent repressor can be expressed in the strain of interest. (Howard *et al* (1995) Gene 166 181-182, Jacobs *et al* (1991) *Mthds in Enz* 204 537-555., Rubin *et al* (1999) *Proc Natl Acad Sci* 1644-1650), Caparon and Scott (1991) *Mthds in Enz* 204 556-586, Norgren, Caparon and Scott, (1989) *Infect and Immun* 57 3846-3850, Biswas *et al*, (1993) *J Bact.* 175 3625-3635.

The vectors are introduced into the cells in accordance with standard techniques such as transformation, co-transformation, direct transfection (*e.g.*, mediated by calcium phosphate or DEAE-dextran) biolistics and electroporation. The recombinant cells are then cultured via standard techniques. Conditions may vary depending upon the prokaryote (*e.g.*, bacterial species) being used. In general, culturing is continued from about 24 to 48 hours at a temperature between about 30 and about 39°C, preferably 37°C. The recombinant cells are cultured in an appropriate complete medium containing a selectable marker to assure a pure population. The strains can also be counter engineered as described below so that if significant levels of the metal independent repressor is not produced a suicide gene

will be de-repressed resulting in the death of the vaccine strain *in situ*. Iron is an essential element for both the bacterial pathogen and its animal host; thus, successful competition for this element is an essential component of the infectious process. The concentration of free iron in the mammalian host available to an invading bacterial pathogen is also extremely limited. As a result, the expression of virulence determinants (e.g., colonization factors, siderophores, hemolysins and toxins) by bacterial pathogens is regulated by iron. Accordingly, the vaccine cultures must be propagated in a complete medium containing iron and other divalent metal cations to facilitate their proliferation.

The vaccines of the present invention may be used in a wide variety of vertebrates, particularly man and domestic animals such as bovine, ovine, porcine, equine, caprine, domestic fowl, *Leporidae*, or other animals that may be held in captivity or may be a vector for a disease affecting a domestic vertebrate.

Pathogens of interest include any specie of microorganism which causes disease and relies entirely or partially upon a repressor mediated regulation of metal-dependent virulence. The present invention relates to methods of vaccinating a host with live recombinant bacteria to elicit protective immunity in the host. The recombinant vaccine can be used to produce humoral antibody immunity, cellular immunity (including helper and cytotoxic immunity) and/or mucosal or secretory immunity.

The manner of application of a vaccine strain may be varied widely, any of the conventional methods for administering an attenuated vaccine being applicable. These include aerosol applications, oral applications, in drinking water, on a solid physiologically acceptable base, or in a physiologically acceptable dispersion, parenterally (e.g., subcutaneously, intramuscularly, intravascularly or intraperitoneally), by injection, by *in ovo* inoculation or the like. The dosage of the vaccine (e.g., number of prokaryotic cells, number of administrations, period of administration, etc.) will vary according to the vaccine strain used and the species, age, and size of host to be protected. Persons skilled in the art will be able to determine the dosage to be administered so as to provide a sufficient immune

response. The recombinant prokaryotes in the composition may be "live" or in "killed" form, as these terms are commonly used in the vaccine art.

The formulation of vaccine strain compositions may also vary widely. Pharmaceutically acceptable vehicles such as water are expected to be useful for oral
5 administration. Other such vehicles including normal saline may be used for parenteral, cloacal or other routes of administration. The vaccine compositions may also be admixed with food for some applications.

The following example is not intended to limit the scope of the invention in any manner.

10 **Example 1**

Attenuation of Virulence in *Mycobacterium tuberculosis* Expressing a Constitutively Active Iron Repressor

This example describes the construction of a candidate strain which is severely attenuated with respect to the parent wild type strain yet which persists long
15 enough to allow the host to mount an immune response.

Summary

With over one-third of the world's population latently infected with *Mycobacterium tuberculosis*, the global burden of tuberculosis is staggering. The emergence of multi-drug resistant strains and the increased susceptibility of the HIV-
20 infected further highlights the need for elucidation of the molecular pathogenesis of *M.tuberculosis* and its virulence genes.

Iron plays a critical role in the regulation of virulence of many bacterial pathogens. (1) In tuberculosis, there is indirect clinical and *in vitro* evidence that iron regulation is important to the virulence of this microbial pathogen. (2-5)
25 Iron is an essential nutrient for the survival of most organisms and has played a central role in the virulence of many infectious disease pathogens. Mycobacterial IdeR is an iron-dependent repressor that shows 80% identity in the functional domains with its corynebacterial homologue, DtxR. In a novel approach to attenuation, *Mycobacterium tuberculosis* has been transformed with a vector
30 expressing an iron-independent, positive dominant, corynebacterial *dtxR* hyperrepressor, DtxR(E175K). Western blots of whole cell lysates of *M.*

tuberculosis expressing the *dtxR*(E175K) gene revealed the stable expression of the mutant protein in mycobacteria. BALB/c mice were infected by tail vein injection with 2×10^5 organisms of wild type or *M.tuberculosis* transformed with the *dtxR* mutant. At 16 weeks, there was a 1.2 log reduction in bacterial survivors in both spleen ($p=0.0002$) and lungs ($p=0.006$) with *M.tuberculosis* DtxR(E175K). A phenotypic difference in colonial morphology between the two strains was also noted. A computerized search of the *M.tuberculosis* genome for the palindromic consensus sequence to which DtxR and IdeR bind, revealed six putative "iron boxes" within 200 base pairs of an open reading frame. Using a gel shift assay, it was shown that purified DtxR binds to the operator region of five of these. Attenuation of *Mycobacterium tuberculosis* can be achieved by the insertion of a plasmid containing a constitutively active, iron-insensitive repressor, DtxR(E175K), which is a homologue of IdeR. The results demonstrate that IdeR controls genes essential for virulence in *M.tuberculosis*.

In a phylogenetically related organism, *Corynebacterium diphtheriae*, iron depletion results in the derepression of virulence genes such as the diphtheria toxin (*tox*) gene by DtxR (diphtheria toxin repressor). The corynebacterial DtxR has a homologue in *M.tuberculosis*, IdeR (iron-dependent repressor). In the amino terminal 140 amino acids that contain the Fe^{2+} and DNA-binding domains of DtxR, IdeR shares 80% identity with DtxR. (6) In 1995, *ideR* was first described by Doukhan *et al.* in conjunction with the *sigA sigB* cluster of genes. (7) Subsequently, the ability of mycobacterial IdeR to bind to the corynebacterial *tox* operator region in a metal ion-dependent manner was demonstrated by gel shift assay. (8) Mutation of *ideR* in *M.smegmatis* resulted in derepressed siderophore production in high iron conditions. (9) These findings parallel those described in corynebacterial *dtxR* and suggest that the homology between these two genes may allow for cross-genus functional complementation.

Using a positive genetic selection system to clone *dtxR* alleles, Sun *et al.* isolated and characterized a series of DtxR mutants created by PCR mutagenesis. (10) One of the mutants which bound to the *tox* operator (*toxO*) and constitutively repressed reporter gene expression in an iron-independent manner was characterized

and found to have a single amino acid substitution of lysine for glutamic acid at position 175 (DtxR(E175K)). In merodiploid strains harboring both wild type *dtxR* and mutant *dtxR*(E175K) genes, Sun *et al.* found the mutant to be dominant over the wild type allele.

5

Methods

Strains, Plasmids, and Cultures The bacterial strains and plasmids used in this study are listed in Table 2. (10-14) *Escherichia coli* cultures were grown in Luria broth or Luria agar supplemented with ampicillin (100g/ml) or hygromycin (200g/ml). *M.tuberculosis* CDC 1551 and *M.smegmatis* cultures were grown in standard Middlebrook 7H9 broth (Difco), supplemented with albumin dextrose complex (ADC), 0.1% glycerol, and 0.05% Tween 80 at 37°C in roller bottles. (15)

Construction of *dtxR* (E175K) Shuttle Vector Plasmid A 1.5 kb *Bam*HI-*Hind*III fragment of DNA from pSDM2 was cloned into pNBV1. The resulting recombinant plasmid, pNBV1/SAD was cloned in *E.coli* DH5 and purified using the Qiagen system (Qiagen, Chatsworth, CA). (16) Purified plasmids were then electroporated into *M.tuberculosis* CDC1551 by standard protocols. (15)

Western Blot Analysis Recombinant *E.coli* and mycobacteria were lysed in 3M urea, 0.5% Triton X-100, 3.25M DTT, 2% Pharmalyte (Pharmacia Biotech, Piscataway, NJ), PMSF (100g/ml) and leupeptin (2g/ml). Using 0.1 mm glass beads, the samples were homogenized twice in a Mini-bead-beater (Biospec Products, Bartlesville, OK) at maximum speed for 1 minute. Samples were centrifuged to remove cellular debris and unlysed cells. After separation by 12% SDS polyacrylamide gel electrophoresis, proteins were transferred to nitrocellulose membranes (Hybond, Amersham, Buckinghamshire, UK) by semi-dry technique (Transblot SD, Hercules, CA) and blocked with 5% non-fat milk in PBS with 0.1% Tween 20 (PBS-T) for 1 hour. Membranes were then incubated overnight in PBS-T with rabbit anti-DtxR polyclonal antibodies at the appropriate concentration at 4°C. (17) After washing, membranes were incubated with horseradish peroxidase-conjugated anti-rabbit antibody diluted in PBS-T for 2 hours. The Supersignal Chemiluminescent Substrate (Pierce, Rockford, IL) was used for autoradiograph development.

Murine Tuberculosis Infection Model 6-8 week-old BALB/c mice were infected by tail vein injection with 2×10^5 organisms of wild type or *M.tuberculosis* DtxR(E175K). Bacterial infection was monitored over a 119-day period. Colony forming units (CFU) in spleen and lungs were assessed at 4 week intervals by serial dilutions of organ homogenates plated on 7H10 Middlebrook agar containing cycloheximide (50 g/ml), carbenicillin (50 g/ml), trimethoprim (20 g/ml), and polymyxin (200 units/ml). (18)

DNA Gel Shift Binding Assay The DNA migration retardation assay was performed as previously described. (19) Purified DtxR protein was isolated by methods as described. (20) Radiolabeled DNA iron box fragments were generated by PCR using 100 ng of ^{32}P -end-labeled primer mixed with 150 ng of unlabeled primer and template DNA from gel-purified 100 bp cold fragments containing the iron box of interest. Binding reactions were carried out in 10mM Tris-OAc (pH7.4), 1mM EDTA, 50mM KCl, 1mM DTT, 5% glycerol, 50g/ml calf thymus DNA. Binding reactions were equilibrated for 30 minutes and then loaded onto a non-denaturing 6% acrylamide gel. (21)

Results

Expression of the corynebacterial *dtxR* gene in mycobacteria

The 1.5 kb corynebacterial DNA fragment cloned in pNBV1/SAD contained 500 bp of 5' non-coding sequences as well as the entire *dtxR*(E175K) open-reading frame. To determine if the corynebacterial mutant *dtxR*(E175K) gene was expressed in mycobacteria, we transformed *M.smegmatis*, a fast growing strain of mycobacteria, with pNBV1/SAD. Whole cell lysates prepared from *M.smegmatis* cultures were separated by 12% SDS PAGE. Figure 4 shows a Western blot developed with polyclonal anti-DtxR antibodies. As illustrated, these antibodies recognize both DtxR and IdeR because of their significant antigenic similarity. Although the deduced molecular mass of IdeR (25.2kDa) differs by only 0.1kDa from DtxR (25.3kDa) we have repeatedly observed anomalous accelerated migration of IdeR in our SDS-PAGE gels in which it runs at 23kDa in spite of its mass of 25kDa. This phenomenon has also been noted by Schmitt *et al.* (8) In preparations from *M.smegmatis* harboring pNBV1/SAD (Fig4, lane 4), two distinct bands appear.

Because *dtxR*(E175K) is expressed from a multicopy plasmid, significantly more DtxR(E175K) protein is made than the chromosomally expressed IdeR. Similar results in *M.tuberculosis* transformed with pNBV1/SAD were also found (results not shown). The *in vitro* growth rate of wild type *M. tuberculosis* was indistinguishable from that of *M. tuberculosis* DtxR(E175K) by the BACTEC radiometric growth monitoring system.

Attenuation of Virulence in *M.tuberculosis* Expressing the Constitutively Active DtxR Hyperrepressor After confirming that the corynebacterial mutant *dtxR* was expressed in transformed mycobacteria, we turned to an *in vivo* animal model to test the effect of the hyperrepressor on virulence. Forty-eight BALB/c mice were inoculated with 2×10^5 CFU of CDC1551 *M.tuberculosis* or *M.tuberculosis* DtxR(E175K) by tail-vein injection. Both animal weights and the tissue burden of surviving bacteria were monitored over time. Mice infected with wild type *M.tuberculosis* began to lose weight beginning at 13 weeks while the *M.tuberculosis* DtxR(E175K)-infected animals initially gained weight, then maintained stable weights for the duration of the experiment. At 17 weeks, there was a statistically significant difference of 1.7 gms ($p=0.006$ by two-tailed *t*-test) between the wild type and DtxR(E175K) groups.

Figures 5A and 5B show the survival of the two *M.tuberculosis* strains in lungs and spleens of mice over time. At 17 weeks, there was a 1.2 log attenuation in virulence of the DtxR(E175K) expressing strain compared with wild type which was statistically significant in both spleen ($p=0.0002$) and lungs ($p=0.006$). Analysis of the colonies from the mouse tissues at 12 weeks showed that 99% of the colonies were hygromycin resistant indicating maintenance of the pNBV1/SAD plasmid. Histopathologic inspection of spleen and lungs of wild type and DtxR(E175K) expressing strains corroborated our CFU data with fewer visible acid fast bacilli at 17 weeks in histologic sections of mouse organs from animals infected with the *M.tuberculosis* DtxR(E175K) than with the wild type.

Differences in Colonial Morphology Between Strains Colonies of *M.tuberculosis* DtxR(E175K) grown from frozen stocks on 7H10 Middlebrook agar showed no difference in growth rate *in vitro* as compared to wild type CDC1551, but

were noted to have a distinct colonial morphology (see figures 6A and 6B). The recombinant strain colonies were rougher and drier-appearing and were more raised and wrinkled than wild type colonies. In addition, yellow pigmentation was also noted in the DtxR(E175K) expressor. Both strains exhibited a spreading phenotype
5 and were crenelated at the periphery.

Identification of Iron Boxes An imperfect palindromic consensus sequence of the "iron box" for DtxR/IdeR has been established by *in vivo* and *in vitro* methods. (8, 22, 23) This consensus sequence is listed at the top of Figure 7. To identify genes that may be regulated by IdeR, we searched the *M.tuberculosis*
10 genome for iron boxes that were in untranslated regions within 200 bp of an open reading frame. We chose two half-site sequences with allowance for a variable number of intervening base pairs for our search. In the 4.41MB of the *M.tuberculosis* genome (24), 58 sequences with acceptable homology to the consensus sequence were identified. Six of these were in untranslated regions and
15 had corresponding downstream open reading frames.

A DNA gel binding assay was used to assess the ability of DtxR to bind to these putative iron-regulated operator regions drawn from the *M.tuberculosis* genome. Figure 8 shows the results of gel binding assays using ³²P-end-labeled 100 bp DNA fragments containing five of the putative iron boxes (IB1-5). Binding of
20 DtxR to the *tox* operator could be abolished with the addition of unlabeled *tox* DNA, but not with nonspecific DNA. All five of these putative iron boxes were bound by DtxR to a similar degree as that observed with the *tox* operator. The iron box upstream of the *narG* homologue, IB6, did not bind to DtxR. (data not shown)

Table 3 identifies the open reading frames (ORF) downstream of these
25 six iron boxes. BLAST searches reveal that these genes encode a PhoP homologue (a transmembrane sensor of a two-component sensor-regulator pair), a homologue of the HtrA serine protease, 16S ribosomal RNA, an alcohol dehydrogenase AdhB, and a homologue of the *M.tuberculosis* 19kDa antigen (a protein shown to be involved in the human immune response to tuberculosis). (25) IB6, which was not shifted by
30 DtxR *in vitro*, appears upstream of a nitrate reductase subunit gene, *narG*.

Discussion

The concentration of free ferrous iron (Fe^{2+}) is extremely limited *in vivo*. For this reason, many pathogenic prokaryotes such as *Vibrio cholerae*, *E.coli*, *Neisseria gonorrhoeae*, and *Corynebacterium diphtheriae* co-regulate virulence gene expression with iron sensing and scavenging systems. (26-28) In *C.diphtheriae*, one such mechanism of iron regulation relies on a repressor, DtxR, which binds to a specific palindromic sequence in the operator regions of the genes that it controls. (29) In low iron states, the metal-ion triggered conformational change that allows it to bind to the DNA is disrupted, the repressor loses affinity for the operator site, and gene expression occurs. Recently, a positive dominant DtxR(E175K) mutant unresponsive to iron was generated by random PCR mutagenesis using a genetic selection system. (10)

Significant amino acid identity between corynebacterial DtxR and mycobacterial IdeR has been described. In the amino terminal 140 amino acids there is a DNA binding helix-turn-helix motif, a primary metal ion binding site and a protein-protein interaction domain. Corynebacterial DtxR and mycobacterial IdeR share 80% amino acid identity in this portion of both proteins. Evidence of functional homology between IdeR and DtxR has been shown previously by Schmitt *et al.* (8)

The results show that the positive dominant DtxR(E175K) iron-independent repressor is expressed in the phylogenetically related mycobacteria. Furthermore, we have shown that it is dominant and constitutively attenuates *M.tuberculosis* in a murine model of infection. Rational attenuation of *M.tuberculosis* provides the opportunity to define specific virulence factors of the organism and the development of live vaccines superior to BCG. However, gene replacement has proven difficult in *M.tuberculosis* due to high rates of illegitimate recombination. Addition of a dominant mutant gene is technically simpler than gene replacement in *M.tuberculosis* and permits comparison of a defined merodiploid strain with an isogenic wild type strain. There are reports of *E.coli* genes introduced into other bacteria to regulate the expression of endogenous genes. In a paper by de Henestrosa *et al.*, a mutant *E.coli recA* gene produced aberrancies in SOS gene

induction when expressed in heterologous gram-negative systems. (30) Although a *M.tuberculosis* strain containing empty plasmid was not compared with wild type *M.tuberculosis*, the *in vitro* Bactec comparison showed no differences in the rate of growth of the mutant strain as compared to wild type. In addition, studies of deletion mutants have shown that plasmid complementation fully restores virulence suggesting that there is little cost to the organism to maintain the plasmid. (31, 32) This strain is the first example of the use of a dominant positive gene from another pathogenic prokaryote to attenuate the virulence of *M.tuberculosis*.

Animal models have shown that inactivation and clearance of virulent *M.tuberculosis* in liver and spleen is effectively accomplished, but that the same cell-mediated immune mechanisms appear relatively ineffective in lungs. These data point to a difference in the intracellular microenvironment of the lung granuloma. (33) It has been postulated from BCG and H37Ra data that avirulent or attenuated strains lack the genes required for effective growth within lung phagocytes. (34) The data suggest that IdeR may regulate genes important for *M.tuberculosis* survival late in lung infection as attenuation seems to increase dramatically at 12 weeks after infection. This may correlate with the onset of granuloma formation in mouse lungs and the need for *M.tuberculosis* to scavenge iron from extracellular rather than intracellular sources. (35)

The *ideR* gene has been found in *M.tuberculosis*, *M.bovis*, and *M.smegmatis*. In *M.smegmatis*, an *ideR* mutant showed defective regulation of siderophore biosynthesis. (9) Potential IdeR binding sites upstream of exochelin biosynthesis genes such as *fxbA* have recently been confirmed. (36, 37) In addition, several IdeR recognition sequences have been identified using computer searches of the *M.tuberculosis* genome. (38) We have similarly identified 6 potential IdeR-binding sites in *M.tuberculosis*, 5 of which demonstrated significant binding with DtxR in a gel shift assay. We postulate that the sixth sequence was unable to bind in our *in vitro* assay because of incorrect spacing between the two relatively well-conserved half-sites. We used DtxR rather than IdeR in this gel-shift assay because we specifically sought to identify genes responsible for the attenuated phenotype of *M.tuberculosis* DtxR(E175K). The predicted ORF downstream of IB-1 encodes a

homologue of *phoP*, a phosphotransfer response regulator. A number of two-component pairs have been shown to regulate virulence pathways in bacterial pathogens. These include BvgA/BvgS in *Bordetella pertussis*, VanR/VanS in *Enterococcus faecium*, PhoP-PhoQ in *Salmonella typhimurium*, and OmpT/EnvZ in *Shigella flexneri*. (39, 40) In *M.tuberculosis*, a two-component pair, *mtrA-mtrB*, has been previously described and appears to play an intracellular role as expression of *mtrA* increases upon entry into macrophages. (41) Furthermore, *phoP*- mutants in *Salmonella* are unable to synthesize many of the proteins expressed on interaction with macrophages. (42) Downstream of IB-2 is *adhB*, an alcohol dehydrogenase. In *Salmonella typhimurium*, it has been postulated that alcohol dehydrogenase genes such as *eutG* may confer a protective role from reactive aldehyde intermediates associated with inflammatory cell activation. (43)

IB-3 lies upstream of an ORF homologous to a HtrA-like serine protease which, in *E.coli* are thought to be required for growth of the organism at high temperature, and may play a role in degrading abnormal proteins within the periplasm. (44, 45) It is a known virulence factor in several organisms including *Salmonella typhimurium*, *Yersinia enterocolitica*, *Brucella abortus*, and *Brucella melitensis*. (46-49) In an animal protection model, a *Salmonella typhimurium htrA* mutant is attenuated and a safe and immunogenic live vaccine strain in mice. (50) Both *Mycobacterium avium* subsp. *paratuberculosis* and *M.tuberculosis* have putative serine proteases with significant homology to HtrA. (24, 51)

IB-4 lies upstream of *rrnA*, a 16S rRNA gene which has been shown to be part of a group of rDNA operons in both slow and fast-growing mycobacteria with hypervariable multiple promoter regions (HMPR). The *M.tuberculosis rrnA* operon has 2 promoters one of which is conditionally induced suggesting complex regulation of this essential gene. (52)

Our results indicate that a dominant positive corynebacterial *dtxR* allele attenuates the virulence of *M.tuberculosis* in a murine model. These data implicate the *M.tuberculosis* IdeR repressor as a regulator of genes essential for full virulence.

Table 2:

	<u>Strain/Plasmid</u>	<u>Genotype/Description</u>
	<u>Source/Reference</u>	
	Plasmids	
5	PNBV1	<i>E.coli</i> -mycobacterial shuttle vector
	(12)	
	Ap ^R , Hy ^R	
	pSDM2	pSC101-derivative containing the
	(10)	
10	<i>dtxR</i> (E175K) gene, Km ^R	
	pNBV1/SAD	pNBV1 containing the
	<i>dtxR</i> (E175K) this paper	
	gene, Ap ^R , Hy ^R	
15	Strains	
	<i>E.coli</i> DH5	F ⁻ <i>recA1</i> , <i>hsdR17</i> , <i>thi-1</i> , <i>gyrA96</i> ,
	(14)	
	<i>supE44</i> , <i>endA1</i> , <i>relA1</i> , <i>recA1</i> ,	
20	<i>deoR</i> , (<i>lacZYA-argF</i>) U169	
	(80 <i>lacZ</i> M15)	
	<i>M.smegmatis</i> mc ² 6 1-2C	transformable variant of mc ² 6
	(13)	
25	<i>M.tuberculosis</i> CDC1551	virulent recent clinical isolate
	(11)	
	<i>M.tuberculosis</i> DtxR(E175K)	pNBV1/SAD
	this paper	
30	Hy hygromycin, Ap ampicillin, Km kanamycin	
	Table 3: Iron Boxes (IB)	

Name	Downstream ORF	Accession Number	Description
IB-1	PhoP homologue	Rv0761c	Two-component phosphotransferase

			regulatory protein
IB-2	AdhB	Rv0757	Alcohol dehydrogenase
IB-3	HtrA homologue	Rv0983	Serine protease, HtrA-antigen family
IB-4	RrnA	MTB00368	16S ribosomal RNA protein
IB-5	Hypothetical protein	Rv3764c	Predicted ORF with 26% similarity to <i>M.tuberculosis</i> 19kDa antigen beginning at base 4,210,314

Example 2

Attenuation of Staphylococcus Infection in a Murine Model

In Example 1 Applicants demonstrated the ability of *in vitro* constructed and tested metal ion independent mutant gene of a normally metal ion dependent transcriptional repressor to attenuate virulence in a pathogenic bacterium of a different species. The metal ion dependent repressor was from *C. diphtheriae* and the pathogenic species was *M. tuberculosis*. The sequence homology of DtxR and the endogenous mycobacterial DtxR -like repressor IdeR is approximately 60% [approaching 90% in the N-terminal half of the repressors]. In example two, applicants have expanded this observation to demonstrate that a dominant metal ion independent repressor such a the mutant E175K DtxR is capable of attenuating virulence across wider species differences in a bacterial strain which co-regulates virulence with iron concentrations and in which there is a Fur or Fur-like repressor. (Heidrich et al (1996) FEMS 140 253-259, Trivier and Courcol (1996) FEMS 141 117-127).

Briefly and a described above in Example 1, partial diploid analysis in reporter host strains of *Escherichia coli* was performed revealing DtxR(E175K) is dominant in strains which carry DtxR/DtxR(E175K). A recombinant partial diploid [dtxR(E175K) / *SirR*] of *Staphylococcus aureus* was constructed carrying the iron independent E175K mutant DtxR. When this strain was used in a series of mouse challenge experiments, it was found to attenuate virulence in a mouse model of staphylococcal infection [See Figures 9A and 9B] When this strain is compared to the parent strain in a mouse skin lesion model there was a significant decrease in CFU isolated from the lesion after 8 days associated with a significant decrease in lesion size compared to *wt* at each time point through out the study [See Figures 9A

and 9B]. These data further demonstrate that activated E175K DtxR or E175K DtxR/DtxR-like (IdeR or SirR) heterodimeric repressors decrease the virulence of pathogenic microorganisms.

It is noteworthy that a dominant metal ion independent repressor from *C. diphtheriae* suppresses virulence in *S. aureus*, especially since the homology of the two repressors is at the amino acid level approaches only 30% as compared to the nearly 60% identity between IdeR from *M. tuberculosis* and DtxR. This means that dominant metal ion independent repressors can be employed across species barriers to selectively control gene expression to produce desired phenotypical changes.

10

References

1. Litwin, C. M. & Calderwood, S. B. (1993) *Clin. Microbiol. Rev.* **6**, 137-149.
2. Kochan, I. (1973) *Curr. Top. Microbiol. Immunol.* **60**, 1-30.
3. Raghu, B., Raghupati, S. & Venkatesan, P. (1993) *Biochem. Mol. Biol. Int.* **31**, 341-3 48.
4. Murray, M. J., Murray, A. B., Murray, M. B. & Murray, C. J. (1978) *Br. Med. J.* **2**, 1113-1115.
5. Gordeuk, V. R., McLaren, C. E., MacPhail, A. P., Deichsel, G. & Bothwell, T. H. (1996) *Blood* **87**, 3470-3476.
6. White, A., Ding, X., vanderSpek, J., Murphy, J. R. & Ringe, D. (1998) *Nature* **394**, 502-6.
7. Doukhan, L., Predich, M., Nair, G., Dussurget, O. & Mandie-Mulec, I. (1995) *Gene* **165**, 67-70.
8. Schmitt, M. P., Predich, M., Doukhan, L., Smith, I. & Holmes, R. K. (1995) *Infect. Immun.* **63**, 4284-4289.
9. Dussurget, O., Rodriguez, M. & Smith, I. (1996) *Mol. Microbiol.* **22**, 535-544.
10. Sun, L., vanderSpek, J. & Murphy, J. R. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 14985-14990

11. Valway, S. E., Sanchez, M. P. C., Shinnick, T. F., Orme, I., Agerton, T., Hoy, D., Jones, J. S., Westmoreland, H. & Onorato, I. M. (1998) *N. Engl. J. Med.* **338**, 633-639.
12. Howard, N. S., Gomez, J. E., Ko, C. & Bishai, W. R. (1995) *Gene* **166**, 181-182.
13. Zhang, Y., Lathigra, R., Garbe, T., Catty, D. & Young, D. (1991) *Mol. Microbiol.* **5**, 381-391.
14. Laboratories, B. R. (1986) in *Bethesda Research Laboratory Focus*, Vol. 8, pp. 9.
15. Jacobs, W. R., Jr., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G. & B.R., B. (1991) *Methods Enzymol.* **204**, 537-555.
16. Ausubel, F. M., R., B., R.E., K., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. (1994) *Current Protocols in Molecular Biology* (Wiley, New York).
17. Tao, X., Boyd, J. & Murphy, J. R. (1992) *Proc. Natl. Acad. Sci. USA*.
18. Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E. & Bishai, W. R. (1999) *Antimicrob. Agents Chemother.* **43**, 85-89.
19. Hendrickson, W. & Schleif, R. F. (1984) *J. Mol. Biol.* **178**, 611-628.
20. Tao, X., Zeng, H.-y. & Murphy, J. R. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 6803-6807.
21. Saviola, B., Seabold, R. & Schleif, R. F. (1998) *J. Mol. Biol.* **278**, 539-548.
22. Tao, X., Schiering, N., Zeng, H.-y., Ringe, D. & Murphy, J. R. (1994) *Mol. Microbiol.* **14**, 191-197.
23. Schmitt, M. P. & Holmes, R. K. (1994) *J. Bacteriol.* **176**, 1141-1149.
24. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., III, C. E. B., Tekaiia, F., Badcock,

- K., Basham, D., Brown, D., Chillingworth, T., R., C., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Kroghs, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M.-A., Roger, J., Rutter, S., Seeger, K., Skelton, J., Squares, R.,
 5 Squares, S., Sulston, J. E., Taylor, K., Whitehead, S. & Barell, B. G. (1998)*Nature* **393**, 537-544.
25. Husson, R. N. & Young, R. A. (1987)*Proc. Natl. Acad. Sci. USA* **84**, 1679-1683.
26. Goldberg, M. B., DiRita, V. J. & Calderwood, S. B. (1990)
 10 *Infect. Immun.* **58**, 55-60.
27. Calderwood, S. B. & Mekalanos, J. J. (1987)*J. Bacteriol.* **169**, 4759-4764.
28. Morse, S. A., Chen, C., LeFaou, A. & Mietzner, T. A. (1988)*Rev. Infect. Dis.* **10**, s306-s310.
- 15 29. Boyd, J., Oza, M. N. & Murphy, J.R. (1990)*Proc. Natl. Acad. Sci. USA* **87**, 5968-5972.
30. de Henestroza, A. R. F., Calero, S. & Barbe, J. (1991)*Mol. Gen. Genet.* **226**, 503-506.
31. Berthet, F.-X., Lagranderie, M., Gounon, P., Laurent-Winter, C., Ensergueix, D., Chavarot, P., Thouron, F., Maranghi, E., Pelicic, V., Portnoi, D.,
 20 Marchal, G. & Gicquel, B. (1998) *Science* **282**, 759-762.
32. Jackson, M., Phalen, S. W., Lagranderie, M., Ensergueix, D., Chavarot, P., Marchal, G., McMurray, D. N., Gicquel, B. & Guilhot, C. (1999)*Infect. Immun.* **67**, 2867-2873.
- 25 33. Collins, F. M. (1993) *Crit. Rev. Microbiol.* **19**, 1-16.
34. Pascopella, L., Collins, F. M., Margin, J. M., Jacobs, W. R. J. & Bloom, B. R. (1993) *Infect. Agents dis.* **2**, 282-284.
35. Long, E. R. (1958) in *The chemistry and chemotherapy of tuberculosis*, ed. Long, E. R. (Williams & Wilkins, Baltimore), pp. 163-182.
- 30 36. Fiss, E. H., Yu, S. & Jacobs, W. R. J. (1994)*Mol. Microbiol.* **14**, 557-569.

37. Dussurget, O., Timm, J., Gomez, M., Gold, B., Yu, S., Sabol, S. Z., Holmes, R. K., Jacobs, W. R. & Smith, I. (1999) *J. Bacteriol.* **181**, 3402-3408.
38. Dussurget, O. & Smith, I. (1998) *Trends Microbiol.* **6**, 354-8.
39. Groisman, E. A. & F., H. (1995) in *Two-component signal transduction*, eds. Hoch, J. A. & Silhavy, T. J. (ASM Press, Washington, D.C.), pp. 319-332.
40. Dziejman, M. & Mekalanos, J. J. (1995) in *Two-Component Signal Transduction*, eds. Hoch, J. A. & Silhavy, T. J. (ASM Press, Washington, D.C.), pp. 305-317.
41. Via, L. E., Curcic, R., Mudd, M. H., Dhandayuthapani, S., Ulmer, R. J. & Deretic, V. (1996) *J. Bacteriol.* **178**, 3314-3321.
42. Buchmeier, N. A. & Heffron, F. (1990) *Science* **248**, 730-732.
43. Stojiljkovic, I., Baumber, A. J. & Heffron, F. (1995) *J. Bacteriol.* **177**, 1357-1366.
44. Lipinska, B., Fayet, O., Baird, L. & Georgopoulos, C. (1989) *J. Bacteriol.* **171**, 1574-1584.
45. Strauch, K. L. & Beckwith, J. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 1576-1580.
46. Johnson, K., Charles, I., Dougan, G., Pickard, K., O'Gaora, P., Costa, G., Ali, T., Miller, I. & Hormaeche, C. (1991) *Mol. Microbiol.* **5**, 401-407.
47. Yamamoto, T., Hanawa, T., Ogata, S. & Kamiya, S. (1996) *Infect. Immun.* **64**, 2980-2987.
48. Robertson, G. T., Elzer, P. H. & II, R. M. R. (1996) *Vet. Microbiol.* **49**, 197-207.
49. Phillips, R. W., Elzer, P. H. & II, R. M. R. (1995) *Microb. Pathog.* **19**, 227-284.
50. Chatfield, S., Strahan, K., Pickard, D., I., C., Hormaeche, C. E. & Dougan, G. (1992) *Microb. Pathog.* **12**, 145-151.
51. Cameron, R. M., Stevenson, K., Inglis, N. F., Klausen, J. & Sharp, J. M. (1994) *Microbiol.* **140**, 1977-1982.

52. Gonzalez-Y-Merchand, J. A., Garcia, M. J., Gonzalez-Rico, S., Colston, M. J. & Cox, R. A. (1997)*J. Bacteriol.* **179**, 6949-6958.

5 All publications cited in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications are herein incorporated by reference to the same extent as if each individual publication were specifically and individually indicated to be incorporated by reference. In addition, U.S. Provisional Application Nos. 60/161,193, filed October 22, 1999, and 60/161,292, filed October 25, 1999, are hereby incorporated by reference.

10 Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the
15 spirit and scope of the present invention as defined by the appended claims.

INDUSTRIAL APPLICABILITY

The present invention is applicable to human and veterinary medicine and more specifically to disease prevention and control of infectious and disease.

CLAIMS

1. A composition comprising a virulent or opportunistic prokaryote in which metal ion-dependent gene regulation confers a growth or an infectious advantage, said prokaryote containing a recombinant DNA molecule comprising a promoter in operable association with a sequence encoding a dominant, metal ion-independent repressor protein or a partially metal ion independent repressor protein, and a carrier.
2. The composition of claim 1 wherein said recombinant DNA molecule is contained in a non-chromosomal vector.
3. The composition of claim 1 wherein said prokaryote is a bacterium.
4. The composition of claim 3 wherein said bacterium is a member of the genus *Mycobacterium*.
5. The composition of claim 4 wherein said bacterium is *Mycobacterium tuberculosis*.
6. The composition of claim 4 wherein said bacterium is *Mycobacterium leprae*.
7. The composition of claim 4 wherein said bacterium is *Mycobacterium avium*.
8. The composition of claim 4 wherein said bacterium is *Mycobacterium paratuberculosis*.
9. The composition of claim 4 wherein said bacterium is *Mycobacterium bovis*.
10. The composition of claim 3 wherein said bacterium is a member of the genus *Staphylococcus*.
11. The composition of claim 10 wherein said bacterium is *Staphylococcus epidermitis*.
12. The composition of claim 10 wherein said bacterium is *Staphylococcus aureus*.

13. The composition of claim 3 wherein said bacterium is a member of the genus *Streptococcus*.

14. The composition of claim 13 wherein said bacterium is *Streptococcus mutans*.

5 15. The composition of claim 13 wherein said bacterium is *Streptococcus pneumoniae*.

16. The composition of claim 1 wherein said sequence encodes a metal ion-independent diphtheria toxin repressor (DtxR) protein.

10 17. The composition of claim 1 wherein said sequence encodes a metal ion-independent or a partially metal ion independent IdeR or SirR repressor protein.

18. The composition of claim 3 wherein said bacterium is a gram-positive bacterium.

15 19. A composition comprising a virulent or opportunistic bacterium in which metal ion-dependent gene regulation confers a growth or an infectious advantage, said bacterium containing a recombinant DNA molecule comprising a promoter in operable association with a sequence encoding a metal or metal ion-independent DtxR protein or a partially metal ion independent DtxR protein, and a carrier.

20 20. An isolated and purified DNA molecule consisting essentially of a sequence encoding a metal ion independent or a partially metal ion independent DtxR or homologue thereof.

21. The DNA molecule of claim 20 wherein said DtxR homolog is IdeR.

25 22. The DNA molecule of claim 20 wherein said DtxR homolog is SirR.

23. A recombinant DNA molecule containing a constitutive promoter element in operable association with the DNA molecule of claim 20.

30 24. A recombinant vector comprising a promoter element in operable association with the DNA molecule of claim 20.

25. The recombinant vector of claim 24 which is a plasmid.

26. A virulent or opportunistic prokaryote in which metal ion-dependent gene regulation confers a growth or an infectious advantage, wherein said prokaryote is transformed with a DNA molecule encoding a dominant, metal ion-independent repressor protein or a partially metal ion-independent repressor protein, and wherein said DNA molecule is expressed in said prokaryote.

27. A method of enhancing protective immunity against infection or disease caused by an opportunistic or virulent prokaryotic pathogen in which metal ion-dependent gene regulation confers a growth or an infectious advantage, comprising administering to an animal the composition of claim 1.

28. The method of claim 27 wherein said animal is a human.

29. The method of claim 27 wherein the prokaryote is in live form.

30. The method of claim 27 wherein the prokaryote is in inactivated form.

31. A method of attenuating or reducing the severity of an infection or disease caused by an opportunistic or virulent prokaryotic pathogen in which metal ion-dependent gene regulation confers a growth or an infectious advantage, comprising administering to an animal the composition of claim 1.

32. The method of claim 1 wherein said animal is a human.

1	15 16	30 31	45 46	60 61	75 76	90
1 mtblder	MNEIVOTTEMYLRTI	YOLEEEGVTPLRARI	AERLDQSGTVSQTV	SRMERDGLLRVAGDR	HLELTEKGRALATAV	MRKHRLAERLLVDVI
2 dtxr	MKDLVDOTTEMYLRTI	YELLEEgvTPLRARI	AERLEQSGTVSQTV	ARMERDGLVVVAGSD-	SLQMTPTGRTLATAV	MRKHRLAERLLTDII
3 staphelisirr	-----	---HTVSCPpPS--T	SEREQ-----ARAL	CLRLLTARSTRRAEL	AGQLAKRGYPEDIGN	RVLDRLLAAVGLVDDT
91	105 106	120 121	135 136	150 151	165 166	180
1 mtblder	GLPWEEVHAACRWE	HVMSEDEVRRLLVKVL	NNPTTSPFCNPiPGL	VELGVGPEGCADDAN	LVRLTELPAGSPVAV	VVRQLTEHVQGDIDL
2 dtxr	GLDINKVHDEACRWE	HVMSEDEVRRLLVKVK	DVSR-SPECNPiPGL	DELGVGNS--DAAAP	GTRVIDAATSMPRKV	RIVQINEIFQVETDQ
3 staphelisirr	DFAEQWQVQSRANAA	KSRRALAAELHAKGV	DDDVITTVLGGIDAG	AERGRAEK--LVRAR	LRREVLLDGDGTD	DEAR VSRRLVAMLARRG-Y
181	195 196	210 211	225 226	240 241	255 256	270
1 mtblder	ITRLKADGAVVPNARV	TVETTPGGGVITVIP	GHENVTLPHEMAHAV	KVEKV	230	
2 dtxr	FQLLDADI RVGSEVE	IVDRD--GHITLSHN	GKD-VELLDLAHTI	RIEEL	223	
3 staphelisirr	GQTLACEVIVIAELAA	ERERR--RV-----	-----	-----	174	

FIGURE 1

1	15	16	30	31	45	46	60	61	75	76	90	
1 M1.	MNDLVDTTEMYLRTI	YDLEEEGIVTPPLAR	IAER-----	PTVSQT	VSRRERDGLRVAGN	RHLELTGKRAMAIA	VMRKHRLAERLLVDV					85
2 TB	MNELVDTEMYLRTI	YDLEEEG-VTPPLAR	IAERLDOSGPTVSQT	VSRRERDGLRVAGD	RHLELTGKRALAIA	VMRKHRLAERLLVDV						89
3 MS	MNDLVDTTEMYLRTI	YDLEEEG-VTPPLAR	IAERLDOSGPTVSQT	VSRRERDGLRVAGD	RHLELTGKRALAIA	VMRKHRLAERLLVDV						89
4 M1b	MTVSCPPSTSER---	EEQARALCLRL	TARS-----	KRAEL	AGQLAKGYPEDIGN	RVLID-----	RLAAG	LVDTDFAEQ-----				70
	91	105	106	120	121	135	136	150	151	165	166	180
1 M1.	IGLPMEEVHAACRM	EHVSEDEVERRLIKV	LNPPTSPPGNPIPG	LLDLGAGPDASANA	KLVRLTTELPSSPVA	VVRQLTEHVQD-DID						174
2 TB	IGLPMEEVHAACRM	EHVSEDEVERRLIKV	LNPPTSPPGNPIPG	LVELGVGPERGADA	NLVRLTTELPAGSPVA	VVRQLTEHVQD-DID						179
3 MS	IGLPMEDEVHAACRM	EHVSEDEVERRLIKV	LNPPTSPPGNPIPG	LVELGVGPERGADA	NLVRLTTELPAGSPVA	VVRQLTEHVQD-DID						179
4 M1b	---WVQS-RRANAA	KSKRALAELHAKGV	DDDVITTVLG-IDA	GAERGR--AEKLVRA	RLRREVLIDDTDEA	RVSRLVAMLA----						148
	181	195	196	210	211	225	226	240	241	255	256	270
1 M1.	LITRLKDTGVPMAR	VTVETSPAGNVIIII	PGHENVTLPHEMAHA	VKEVKV----								225
2 TB	LITRLKDTGVPMAR	VTVETSPAGNVIIII	PGHENVTLPHEMAHA	VKEVKV----								230
3 MS	LIGRLKAGVPMAR	VTVEANNNGVMIVI	PGHEQVELPHMAHA	VKEVKV----								233
4 M1b	---RKGQGLACEV	VIAELAEERERRRV-	-----	-----								174

FIGURE 2

	10	20	30	40	50	60	
B1 DtxR		MKDLVDTTTEM	YLRTIYELEE	EGIVPLRARI	AERLEQSGPT	VSQTVARMER	DGLVHVSPDR
Cd DtxR		MKDLVDTTTEM	YLRTIYELEE	EGVTPLRARI	AERLEQSGPT	VSQTVARMER	DGLVVVASDR
Mt IdeR		MNELVDTTTEM	YLRTIYDLEE	EGVTPLRARI	AERLDQSGPT	VSQTVSRMER	DGLLRVAGDR
Ms IdeR		MNDLVDTTTEM	YLRTIYDLEE	EGVVPLRARI	AERLDQSGPT	VSQTVSRMER	DGLLHVAGDR
M1 IdeR		MNDLVDTTTEM	YLRTIYDLEE	EGIVTPLRARI	AER PT	VSQTVSRMER	DGLLRVAGNR
S1 DesR		MSGLIDTTTEM	YLRTILELEE	EGVVPMRARI	AERLDQSGPT	VSQTVARMER	DGLVSVAAADR
Se SirR	M	LTEEKED	YLKAILTNDG	DVSFVSNKKL	SQFLNIKPPS	VSEMVGRLEK	EGYVETKHYK
Sa SirR	M	LTEEKED	YLKAILTNNG	DKNFVTNKIL	SQFLNIKPPS	VSEMVGRLEK	AGYVETKPYK
Ef	M	TPNRED	YKLIFELGG	DEVKVNKKQI	VSGLDVSAAS	VSEMISKLVK	EDLVEHSPYQ
Sg	M	TPNKED	YLKCLYELGT	RHNKITNKEI	AGLMQVSPPA	VTEMMKKLLA	EELLIKDKKA
Sm	M	TPNKED	YLKIIYELSE	RDEKISNKQI	AEKMSVSAPA	VSEMVKKLLL	EDLVLKDKQA
Spn	M	TPNKED	YLKCIYEIGI	DLHKITNKEI	AARMQVSPPA	VTEMIKRMKS	ENLILKDKEC
Spy	M	TPNKED	YLKCIYEIGI	DLHKITNKEI	AARMQVSPPA	VTEMIKRMKS	ENLILKDKEC
CONSENSUS		M--*-----E*	YL*-I*-----	-----NK*-	*-----P-	*****--*	--L-----
		70	80	90	100	110	120
B1 DtxR		SLEMTPEGRS	LAIAMVRNDR	LAERLLTDII	GLDIHKVHDE	ACRWEHVMSD	EVERRLVEVL
Cd DtxR		SLQMTPTGRT	LATAVMRKHR	LAERLLTDII	GLDINKVHDE	ACRWEHVMSD	EVERRLVKVL
Mt IdeR		HLELTEKGRA	LAIAMVRKHR	LAERLLVDVI	GLPWEEVHAE	ACRWEHVMSD	DVERRLVKVL
Ms IdeR		HLELTDKGRA	LAVAVMRKHR	LAERLLVDVI	LPWEDGVHAE	ACRWEHVMSD	EVERRLVQVL
M1 IdeR		HLELTTKGRA	MAIAMVRKHR	LAERLLVDVI	GLPWEEVHAE	ACRWEHVMSD	DVERRLIKVL
S1 DesR		HLELTDGRR	LATRVMRKHR	LAECLLVDVI	GLEWEQVHAE	ACRWEHVMSD	AVERRVLELL
Se SirR		GARLTEEGLK	QTLDIKRRH	LLRLFLIEIL	QYNWEEVHQE	AEILEHRISD	LFVERLDKIL
Sa SirR		GVRLEDGLT	HTLDII RHR	LLEFLIEIL	KYNWEEVHQE	AEILEHRISD	LFVERLDSLL
Ef		GVQLTEKGLK	KASTLIRKHR	IWEVFLVEHL	NYTWNDVHEE	AEVLEHVTSD	TLVNRADYL
Sg		GYLLTDLGLK	LVSDLYRKHR	LIEVFLVHHL	GYTTEEIHEE	AEVLEHTVSD	HFVERLDQLL
Sm		GYLLTKKGQI	LASSLYRKHR	LIEVFLMNHL	NYTADEIHEE	AEVLEHTVSD	VFVERLDKFL
Spn		GYLLTDLGLK	LVSELYRKHR	LIEVFLVHHL	DYTSDQIHEE	AEVLEHTVSD	LFVERLDKLL
Spy		GYLLTDLGLK	LVSELYRKHR	LIEVFLVHHL	DYTSDQIHEE	AEVLEHTVSD	LFVERLDKLL
CONSENSUS		---LT-G--	-----**HR	L--*L---L	-----H-E	A--*EH-S*	---R***-L
		130	140	150	160	170	180
B1 DtxR		DDVHRSPFGN	PIPGLEIGL	DQADEPDSGV	RAIDLPLGEN	LKARIVQLNE	ILQVDLEQFQ
Cd DtxR		KDVSRSPFGN	PIPGLELGV	GNSDAAAPGT	RVIDAATSMP	RKVRIVQINE	IFQVETDQFT
Mt IdeR		NNPTTSPFGN	PIPGLELGV	GPEPGADDAN	LVRLTELPAG	SPVAVVVRQL	TEHVQGDIDL
Ms IdeR		ENPTTSPFGN	PIPGLELAV	TPGVNTEDVS	LVRLTELPVG	MPVAVVVRQL	TEHVQGDIDL
M1 IdeR		NNPTTSPFGN	PIPGLLDLGA	GPDASAANAK	LVRLTELPVG	SPVAVVVRQL	TEHV DDIDL
S1 DesR		RHPTESPYGN	PIPGLEELGE	TDGADPFLDE	GMVSLADLDP	GQEGKTVVVR	RIGEPIQTDA
Se SirR		NFPKTCPHGG	VIP	R GNSDAAAPGT	SILNFEPGER	VTVRRV RRDK	TELL
Sa SirR		NFPETCPHGG	VIP	R NNEYKEKYIT	TILNYEPGDI	VTIKRV RDK	TDLL
Ef		NHPEFCPHGG	VIPEDNQPIH	EEKRQTLTDY	PVGTKIRIAR	VLDEKELLDY	LVSIDLNIQE
Sg		DYPKACPHGG	TIPAKGELLV	EKHKLTLEEA	KEKGDYILAR	VHDNFDLLTY	LERNGLQVGK
Sm		NYPKVCPHGG	TIPGHGQPLV	ERYRTTLKGV	TEMGVYLLKR	VQDNFQLLKY	MEQHHLKIGD
Spn		GFPKTCPHGG	TIPAKGELLV	EINNPLPLADI	KEAGAYRLTR	VHDSFDILHY	LDKHSLLHIGD
Spy		GFPKTCPHGG	TIPAKGELLV	EINNPLPLADI	KEAGAYRLTR	VHDSFDILHY	LDKHSLLHIGD
CONSENSUS		--P--*P*G*	-IP-----*	-----	-----	-----	-----

FIGURE 3

	190	200	210	220	230
B1 DtxR	ALTDAGVEIG	TEVDIINEQG	RVVITHNGSS	VELIDDLAHA	VRVEKVEG
Cd DtxR	QLLDADIRVG	SEVEIVDRDG	HITLSHNGKD	VELDDDLAHT	IRIEEL
Mt IdeR	ITRLKDAGVV	PNARVTVETT	PGGGVTVIVIP	GHENVTLPHE	MAHAVKVEKV
Ms IdeR	IGRLKEAGVV	PNARVTVEAN	NNGGVMIVIP	GHEQVELPHH	MAHAVKKKVE KVEKV
M1 IdeR	ITRLKDTGVV	PNARVTVETS	PAGNVIIIIP	GHENVTLPHE	MAHAVKVEKV

S1 DesR	QLMYTLRRAG	VQPGSVSVST	ESAGGVLVGS	GGEAAELEAD	TASHVFVAKR
Sa SirR	VYLSSKDIYI	GNTVEIVSKD	DTNKVIILKR	NDIVTILSYE	NAMNIFAEK
Sa SirR	IYLSSKDISI	GNEVEIVSKD	EMNKVIIIKR	NDNVIIIVSYE	NAMNMFAEK
Ef	EYTIKEIAAY	EGPITIYNEN	KELSVSFKAA	NTIFVEPLIR	ESEEN
Sg SgoR	TIRFLGYDDF	SHLYSLEVDG	QEIQLAQPIA	QQIYVEKI	
Sm SloR	ELRLLEYDAF	AGAYTIEKDG	EQLQVTSAVA	SQIYIEKKAY	
Spn	QLQVKQFDGF	SNTFTILSND	EDLQVNMDIA	KQLYVEKIN	
Spy	QLQVKQFDGF	SNTFTILSND	EDLQVNMDIA	KQLYVEKIN	

CONSENSUS -----

FIGURE 3 cont.




FIGURE 4




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B

G T A G G T T A G G C T - A A C C T A T																				Consensus Sequence
T	T	A	G	G	T	T	A	G	G	C	T	-	A	A	C	C	T	A	A	Published Consensus
T	T	A	G	G	A	T	A	G	C	T	T	-	T	A	C	C	T	A	A	<i>tox</i> PO <i>C.diphtheriae</i>
T	T	A	G	G	T	T	A	G	G	C	T	-	C	A	C	C	T	A	A	<i>desA</i> PO <i>S.pilosus</i>
C	C	A	G	G	G	T	A	T	C	T	A	-	A	T	C	C	T	G	T	16S ribosomal RNA
G	C	A	G	G	C	C	A	G	T	G	A	-	A	A	C	C	T	G	T	19 kDa antigen
A	C	A	G	G	T	G	G	T	G	C	T	C	A	A	C	C	A	C	G	<i>htrA</i> homologue
G	A	A	G	G	T	A	A	C	G	T	T	C	A	A	C	C	A	A	T	<i>phoP</i> homologue
G	C	A	G	G	T	G	A	C	C	G	T	C	A	A	C	C	G	A	T	<i>adhB</i> homologue
G	A	A	G	G	T	C	A	A	C	C	A	-	A	A	C	A	A	G	A	<i>narG</i> homologue

FIGURE 7




FIGURE 8




FIGURE 9A




FIGURE 9B




FIGURE 4

6/10




FIGURE 5A




FIGURE 5B

7/10



FIGURE 6A




FIGURE 6B

G T A G G T T A G G C T - A A C C T A T																				Consensus Sequence
T	T	A	G	G	T	T	A	G	G	C	T	-	A	A	C	C	T	A	A	Published Consensus
T	T	A	G	G	A	T	A	G	C	T	T	-	T	A	C	C	T	A	A	<i>tox</i> PO <i>C.diphtheriae</i>
T	T	A	G	G	T	T	A	G	G	C	T	-	C	A	C	C	T	A	A	<i>desA</i> PO <i>S.pilosus</i>
C	C	A	G	G	G	T	A	T	C	T	A	-	A	T	C	C	T	G	T	16S ribosomal RNA
G	C	A	G	G	C	C	A	G	T	G	A	-	A	A	C	C	T	G	T	19 kDa antigen
A	C	A	G	G	T	G	G	T	G	C	T	C	A	A	C	C	A	C	G	<i>htrA</i> homologue
G	A	A	G	G	T	A	A	C	G	T	T	C	A	A	C	C	A	A	T	<i>phoP</i> homologue
G	C	A	G	G	T	G	A	C	C	G	T	C	A	A	C	C	G	A	T	<i>adhB</i> homologue
G	A	A	G	G	T	C	A	A	C	C	A	-	A	A	C	A	A	G	A	<i>narG</i> homologue

FIGURE 7

9/10




FIGURE 8

10/10




FIGURE 9A




FIGURE 9B

INTERNATIONAL SEARCH REPORT

International application N .
PCT/US00/29231

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/00, 39/02; C12N 15/62, 15/31, 15/63

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/ 93.42, 165.1, 168.1, 183.1, 193.1, 237.1, 243.1, 248.1; 435/ 7.33, 36, 253.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, EAST, DIALOG, STN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,894,443 A (GREENFIELD et al.) 16 January 1990, see whole document.	1-32
A	US 5,196,338 A (ANILIONIS et al.) 23 March 1993, see whole document.	1-32



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 JANUARY 2001

Date of mailing of the international search report

06 FEB 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
Shawn P. Foley
SHAWN P. FOLEY

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/29231

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/ 93.42, 165.1, 168.1, 183.1, 193.1, 237.1, 243.1, 248.1; 435/ 7.33, 36, 253.1